<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="obstetrics-and-gynaecology" lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher">JOHS</journal-id>
<journal-id journal-id-type="nlm-ta">Journ of Health Scien</journal-id>
<journal-title-group>
<journal-title>Journal of HealthCare Sciences</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Journ of Health Scien</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">2231-2196</issn>
<issn pub-type="opub">0975-5241</issn>
<publisher>
<publisher-name>Radiance Research Academy</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">266</article-id>
<article-id pub-id-type="doi">http://dx.doi.org/10.52533/JOHS.2024.40204</article-id>
<article-id pub-id-type="doi-url"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Obstetrics & Gynaecology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Assessing the Efficacy of Tranexamic Acid in Minimizing Perioperative Blood Loss in Ovarian Cancer Surgery: A Systematic Review of Randomized Controlled Trials and Meta-Analysis
</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ibrahem</surname>
<given-names>Azhar M. Al</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Qasem</surname>
<given-names>Basmah A.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Almadabighi</surname>
<given-names>Raneem A.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Almasud</surname>
<given-names>Dalia H.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alomar</surname>
<given-names>Lujain H.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sindi</surname>
<given-names>Mohammad H.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Barakat</surname>
<given-names>Abdulmalik S.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bajaaj</surname>
<given-names>Reem A.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alhaji</surname>
<given-names>Alreem M.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alhumaid</surname>
<given-names>Sally A.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alfawaz</surname>
<given-names>Rand M.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kishi</surname>
<given-names>Nihad A. Al</given-names>
</name>
</contrib>
</contrib-group>
<pub-date pub-type="ppub">
<day>29</day>
<month>02</month>
<year>2024</year>
</pub-date>
<volume>4</volume>
<issue>2</issue>
<fpage>143</fpage>
<lpage>153</lpage>
<permissions>
<copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement>
<copyright-year>2009</copyright-year>
<license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract>
<p>Introduction: Ovarian cancer stands as the predominant gynecological malignancy on a global scale a global gynecological malignancy with a >60% mortality rate, often necessitates aggressive surgeries like maximal cytoreduction to enhance survival. However, these procedures pose bleeding risks requiring blood transfusions. Tranexamic acid (TXA), a long-established clotting inhibitor, offers potential solutions. Our objective is to assess TXA__ampersandsign#39;s safety and efficacy in minimizing perioperative bleeding during ovarian cancer surgery through a thorough literature review.
Methods: This systematic review adhered to PRISMA guidelines. It encompassed RCTs involving women aged 18+ undergoing ovarian cancer surgery with tranexamic acid versus placebo or no treatment. We conducted a comprehensive electronic search in PubMed, Cochrane Library, and MEDLINE using MeSH terms and related keywords to identify relevant studies, with no language limitation.
Results: We focused on four RCTs spanning from 2008 to 2023, exclusively involving females, with group sizes ranging from 60 to 150. The tranexamgroupsid group exhibited a notable reduction in perioperative bleeding and required fewer blood transfusions than the control group. However, no remarkable variances were identified in vomiting, hematoma, or bleeding rates between the two groups. These findings offer valuable insights with implications for medical practice and future research.
Conclusion: In conclusion, A systematic analysis of randomized controlled trials related to surgical treatments in ovarian cancer reveals robust evidence favoring tranexamic acid for reducing both intraoperative and the need for blood transfusion. However, future research should include long-term follow-up studies to gauge its influence on patient survival, disease recurrence, and other vital clinical parameters.
</p>
</abstract>
<kwd-group>
<kwd>Ovarian cancer</kwd>
<kwd> ovarian neoplasms</kwd>
<kwd> tranexamic acid</kwd>
</kwd-group>
</article-meta>
</front>
</article>